Certain drugs used to treat HIV may have a role in preventing SARS-CoV-2 infections, according to preliminary data that may help explain why people living with the condition have not appeared to be at higher risk for serious COVID-19 despite being generally more vulnerable to infections. Additionally, having COVID-19 and influenza at the same time puts hospitalized adults at much greater risk of critical illness and death compared to having COVID-19 without the flu, researchers reported in The Lancet.

As Pfizer’s antiviral Paxlovid tablets against COVID-19 roll out, the company indicated it had halted the development of the intravenous variation of the drug, PF-07304814. In other news, SaNOtize Research & Development Corp. and Glenmark Pharmaceuticals Ltd. announced that a Phase III trial of Nitric Oxide Nasal Spray (NONS) hit the primary endpoint.

Evoke Pharma Inc., a specialty pharmaceutical company primarily focused on treatments for gastrointestinal (GI) diseases, and EVERSANA Life Science Service LLC, an independent provider of global commercial services to the life science industry, announced an extension of their agreement. The companies will continue collaborating on the commercialization and distribution of Gimoti (metoclopramide) nasal spray in the United States through the end of 2026.

A COVID-19 vaccine that can be produced locally in low-income and middle-income countries is yielding promising results in early clinical trials, researchers say. Other researchers believe that once the body has been “primed” by mRNA vaccines to recognize and attack the coronavirus, a booster containing purified versions of virus’ spike protein that could be given intranasally would have many advantages.

Following years of preparation, scientists from Brigham and Women’s Hospital are ready to start a clinical trial that will evaluate the use of an intranasal vaccine to prevent Alzheimer’s disease (AD).


Oyster Point Pharma Inc.’s treatment for dry eye disease became the first U.S. approved nasal spray for the chronic condition on Oct. 18, sending the drug developer’s shares higher.

Russia will test a nasal spray form of the Sputnik V vaccine against Covid-19 among adult volunteers, according to a state document published on Oct. 12, as the country struggles to rein in rising numbers of infections and deaths.

Codagenix Inc. announced favorable safety and immunogenicity data from a Phase I dose-escalation trial of the company’s single-dose intranasal COVI-VAC vaccine, and London-based pHOXBIO Ltd. reported results from a pivotal phase II/III study of the novel prophylactic nasal spray pHOXWELL.

Indian vaccine maker Bharat Biotech’s nasal Covid-19 vaccine candidate received regulatory approval for mid-stage to late-stage trials, the government’s ministry of science and technology said in a statement on Aug. 13.

Oyster Point’s New Drug Application (NDA) for the dry eye disease therapy OC-01 was accepted for FDA regulatory review on the back of positive Phase III data.